Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> MutationCaroline Robert, Paolo A. Ascierto, Georgina V. Long et al.|New England Journal of Medicine|2014Cited by 5.3k
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced MelanomaCaroline Robert, Victoria Atkinson, Georgina V. Long et al.|Journal of Clinical Oncology|2020Cited by 226
Predictors of responses to immune checkpoint blockade in advanced melanomaNicolas Jacquelot, Laurence Zitvogel, Moshe Sade-Feldman et al.|Nature Communications|2017Cited by 201
Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanomaGeorgina V. Long, Caroline Robert, Victoria Atkinson et al.|Journal of Translational Medicine|2015Cited by 53
Unrestrained cleavage of Roquin-1 by MALT1 induces spontaneous T cell activation and the development of autoimmunityHenrik Schmidt, Vigo Heissmeyer|Proceedings of the National Academy of Sciences|2023Cited by 11